Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumour control and with acceptable rectal toxicity compared to conventional fractionation.
Trial Start Date: March, 2012
Trial Phase: Phase 2
Medical Conditions: High-risk Prostate Cancer
Lead Sponsor: Alberta Health Services
See more details here.
No comments:
Post a Comment